A Phase 1, Multi-center, Open-Label Dose Escalation Study of SYN004 in Patients With Solid Tumors to Evaluate the Safety, Immunogenicity and Pharmacokinetics of SYN004 Following Administration of Eight Intravenous Doses
Phase of Trial: Phase I
Latest Information Update: 08 Nov 2017
At a glance
- Drugs SYN 004 Synermore Biologics (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Synermore Biologics
- 01 Nov 2017 Planned End Date changed from 1 Dec 2017 to 1 Jul 2018.
- 01 Nov 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Jan 2018.
- 18 Aug 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.